It could happen that 2 companies bidding together could meet Joe's ASK price.
Amylin wanted close to 35$. BMY was stuck at 28$/share in June,2012 after initial bid of 22$/share in Feb.2012.
Goldman Sachs got BMY and AZN to bid jointly--BMY has rights in USA--AZN has rights to sell diabeties drugs overseas.The final price was 7 billion$.
For Amarin--there are markets outside Japan--Epadel-Mochida has market in Japan.
So biggest opportunity is USA, followed by Europe/Mid East and then Brazil,Mexico,Argentina etc.
Until we have positive results from Reduce-IT study-- 60-65% sales will come from USA.
If Reduce-It study is successful--then it may be 50% in USA and 50% overseas.
My hunch is that it will be one co. that buys AMRN in next 2-4 months.
I think it will be Pfizer.